Literature DB >> 25641377

Transarterial chemoembolization aggravated peritumoral fibrosis via hypoxia-inducible factor-1α dependent pathway in hepatocellular carcinoma.

Kai Qu1, Zhaoyong Yan, Yousheng Wu, Yibing Chen, Ping Qu, Xinsen Xu, Peng Yuan, Xiaojun Huang, Jinliang Xing, Hongxin Zhang, Chang Liu, Jing Zhang.   

Abstract

BACKGROUND AND AIM: It was commonly accepted that chemotherapeutic cytotoxicity was the main cause for hepatic failure in hepatocellular carcinoma patients after repeated transarterial chemoembolization (TACE). However, the effect of embolization-induced hypoxia on liver cirrhosis has rarely been concerned.
METHODS: Serum levels of alanine aminotransferase, aspartate aminotransferase, and albumin were used to detect liver injury. Hepatic artery ligation was performed in carbon tetrachloride-induced rat hepatic fibrosis model to mimic the effect of hepatic hypoxia on liver fibrosis after TACE. Sirius Red staining and immunohistochemical analysis of alpha-smooth muscle actin (α-SMA) were used to detect the activation of hepatic stellate cells. Moreover, the expression of hypoxia and fibrosis-related molecules were analyzed at protein and/or mRNA level.
RESULTS: Patients showed a significant increase in alanine aminotransferase and aspartate aminotransferase (P = 0.006), accompanied by a decrease in albumin (P = 0.005) after repeated TACE. Hepatic artery ligation significantly promoted carbon tetrachloride-induced rat liver fibrosis progression as indicated by Sirius Red and α-SMA staining, as well as increased expression of hypoxia-inducible factor (HIF)-1α, transforming growth factor (TGF)-β1, and vascular endothelial growth factor (VEGF). Conditioned media of hypoxia-treated L02 cells induced the expression of Collagen I and α-SMA in LX-2 cells, which was inhibited by HIF-1α small interfering RNA. Finally, HIF-1α inhibitor LW6 attenuated the hypoxia-induced fibrosis progression in vivo.
CONCLUSION: Our data demonstrate that TACE-induced hepatic hypoxia aggravates the fibrosis progression in peritumoral liver tissue, thus leads to the deterioration of liver function. Intervention of HIF-1α might be a valuable strategy to optimize the efficacy and reduce the complication of TACE.
© 2014 Journal of Gastroenterology and Hepatology Foundation and Wiley Publishing Asia Pty Ltd.

Entities:  

Keywords:  hepatocellular carcinoma; hypoxia; liver fibrosis; transarterial chemoembolization

Mesh:

Substances:

Year:  2015        PMID: 25641377     DOI: 10.1111/jgh.12873

Source DB:  PubMed          Journal:  J Gastroenterol Hepatol        ISSN: 0815-9319            Impact factor:   4.029


  11 in total

1.  Transarterial embolization combined with RNA interference targeting hypoxia-inducible factor-1α for hepatocellular carcinoma: a preliminary study of rat model.

Authors:  Jia-Yan Ni; Lin-Feng Xu; Wei-Dong Wang; Qiao-Sheng Huang; Hong-Liang Sun; Yao-Ting Chen
Journal:  J Cancer Res Clin Oncol       Date:  2016-09-16       Impact factor: 4.553

2.  Double Knockdown of PHD1 and Keap1 Attenuated Hypoxia-Induced Injuries in Hepatocytes.

Authors:  Jing Liu; Yiping Li; Lei Liu; Zhi Wang; Chuanbing Shi; Zhengyuan Cheng; Xiaoyi Zhang; Fengan Ding; Ping Sheng Chen
Journal:  Front Physiol       Date:  2017-05-10       Impact factor: 4.566

3.  Postoperative adjuvant TACE for patients of hepatocellular carcinoma in AJCC stage I: friend or foe? a propensity score analysis.

Authors:  Yifan Tong; Zheyong Li; Yuelong Liang; Hong Yu; Xiao Liang; Hui Liu; Xiujun Cai
Journal:  Oncotarget       Date:  2017-04-18

Review 4.  Role of Hypoxia-Inducible Factors in the Development of Liver Fibrosis.

Authors:  Katherine J Roth; Bryan L Copple
Journal:  Cell Mol Gastroenterol Hepatol       Date:  2015-09-25

5.  Activation of TWIST Transcription by Chromatin Remodeling Protein BRG1 Contributes to Liver Fibrosis in Mice.

Authors:  Wenhui Dong; Ming Kong; Yuwen Zhu; Yang Shao; Dongmei Wu; Jun Lu; Junli Guo; Yong Xu
Journal:  Front Cell Dev Biol       Date:  2020-05-13

6.  Short- and long-term effects of transarterial chemoembolization on portal hypertension in patients with hepatocellular carcinoma.

Authors:  Bernhard Scheiner; Gregor Ulbrich; Mattias Mandorfer; Thomas Reiberger; Christian Müller; Fredrik Waneck; Michael Trauner; Claus Kölblinger; Arnulf Ferlitsch; Wolfgang Sieghart; Markus Peck-Radosavljevic; Matthias Pinter
Journal:  United European Gastroenterol J       Date:  2019-03-21       Impact factor: 4.623

7.  miR‑212 promotes renal interstitial fibrosis by inhibiting hypoxia‑inducible factor 1‑α inhibitor.

Authors:  Yun Zhang; Guo-Xin Zhang; Li-Shuang Che; Shu-Han Shi; Yue-Ting Li
Journal:  Mol Med Rep       Date:  2021-01-26       Impact factor: 2.952

8.  Transcatheter Arterial Chemoembolization in Combination With High-Intensity Focused Ultrasound for Intermediate and Advanced Hepatocellular Carcinoma: A Meta-Analysis.

Authors:  Yun-Bing Wang; Rong Ma; Zhi-Biao Wang; Qiu-Ling Shi; Lian Zhang; Wen-Zhi Chen; Jian-Ping Gong; Jin Bai
Journal:  Front Oncol       Date:  2022-03-28       Impact factor: 6.244

9.  Longitudinal Analysis of the Effect of Repeated Transarterial Chemoembolization for Liver Cancer on Portal Venous Pressure.

Authors:  Constantine Frangakis; Jae Ho Sohn; Ahmet Bas; Julius Chapiro; Ruediger E Schernthaner; MingDe Lin; James P Hamilton; Timothy M Pawlik; Kelvin Hong; Rafael Duran
Journal:  Front Oncol       Date:  2021-11-05       Impact factor: 6.244

10.  Prognostic value of splenic volume in hepatocellular carcinoma patients receiving transarterial chemoembolization.

Authors:  Hai-Tao Dai; Bin Chen; Ke-Yu Tang; Gui-Yuan Zhang; Chun-Yong Wen; Xian-Hong Xiang; Jian-Yong Yang; Yan Guo; Run Lin; Yong-Hui Huang
Journal:  J Gastrointest Oncol       Date:  2021-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.